Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market

Pfizer (PFE) announced that it is voluntarily withdrawing all lots of its sickle-cell disease (SCD) medication Oxbryta (voxelotor) from all markets where the drug is approved.Why PFE is Withdrawing the Drug All of a Sudden?This decision is based on the totality of clinical data, which shows that the benefit of the drug no longer outweighs the risks associated with its use. Per management, the data reflected an imbalance in vaso-occlusive crises (a common and painful complication of SCD) and fatal events tha ...